Toxicity of subcutaneously administered recombinant human interleukin-2 in rats

Toxicological Sciences

Volumn 42, Issue 1, 1998, Pages 57-63

  Wolfgang, Grushenka H I ^a   McCabe, Rene D ^a   Johnson, Dale E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibody formation; IL 2 toxicity; Lymphocytosis; Rat; Recombinant human interleukin 2; Subcutaneous administration

Indexed keywords

CYTOCHROME P450; RECOMBINANT INTERLEUKIN 2; SINGLE STRANDED DNA; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CLINICAL CHEMISTRY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; FEMALE; HEMATOLOGY; HISTOPATHOLOGY; IMMUNOREGULATION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; MORTALITY; NONHUMAN; ORGAN WEIGHT; OUTCOMES RESEARCH; RAT; SPLEEN WEIGHT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALIA;

EID: 0031892262     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1006/toxs.1997.2419     Document Type: Article

References (25)

1. Andersen, P. M., and Sorenson, M. A. (1994). Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokin. 27, 19-31.
2. Anderson, T. D. (1992). Structure and function of interleukin-2 In Cytokines in Health and Disease (S. L. Kunkel and D. G. Remick, Eds.), pp. 27-60. Dekker, New York.
3. Anderson, T. D., Hayes, T. J., Gately, M. K., Bontepo, J. M., Stern, L, L., and Truitt, G. A. (1988). Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Lab Invest. 59, 598-612.
4. Anderson, T. D., and Hayes, T. J. (1989). Toxicity of human recombinant interleukin-2 in rats. Lab Invest. 60, 331-346.
5. Anderson, T. D., Hayes. T. J., Powers, G. D., Gately, M. K., Tudor, R., and Rushton, A. (1993). Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. Int. Rev. Exp. Pathol. 34A, 57-77.
6. Bocci, V., Muscettola. M., and Naldini. A. (1986). The lymphatic route-Ill. Pharmacokinetics of human natural interferon-beta injected with albumin as a retarder in rabbits. Gen. Pharmacol. 17, 445-448.
7. Caligiuri, M. A. (1993). Low-dose recombinant interleukin-2 therapy: Rationale and potential clinical applications. Semin. Oncol. 20, 3-10.
8. 125 and native interleukin-2. J. Biol. Respir. Madif. 4, 96-109.
9. Harada, Y., and Yahara, I. (1993). Pathogenesis of toxicity with humanderived interleukin-2 in experimental animals. Int. Rev: Exp. Pathol. 34A, 37-55.
10. Investigator's Brochure (1996). Proleukin (aldesleukin). Recombinant Human Interleukin-2 (rhIL-2). Infectious Disease.
11. Kovacs. J. A., Vogel, S., Albert. J. M., Falloon, J., Davey, R. T., Walker, R. E., Polis, M. A., Spooner, K., Metcalf, J. A., Baseler, M., Fyfe, G., and Lane, C. H. (1996). Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Eng. J. Med. 335, 1350-1356.
12. Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinhausen, S. E., Vetto, J. T., Seipp, C. A., and Rosenberg, S. A. (1986). Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58, 2764-2772.
13. Margolin, K. A., Rayner. A. A., Hawkins, M. J., Atkins, M. B., Dutcher. J. P., Fisher, R. L, Weiss, G. R., Doroshow, J. H., Jaffe, H. S., Roper, M., Parkinson, D. R., Wiernik, P. H., Creekmore, S. P., and Boldt, D. H. (1989). Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J. Clin. Oncol. 7, 486-498.
14. Mertelsmann, R., and Weite, K. (1986). Human interleukin 2: Molecular biology, physiology and clinical possibilities. Immunobiology 172, 400-419.
15. Physicians Desk Reference. (1995). 49 ed., pp. 865-869. Medical Economics Co., Oradell, NJ.
16. Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Kloths, K., and Mark, D. F. (1984). Biological activity of recombinant human interleukin 2 produced in Escherichia coli. Science 223, 1412-1415.
17. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold. P. M. J., Linehan, W. M., et al. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-485.
18. Siegel, J. P., and Puri, R. K. (1991). Interleukin-2 toxicity. J. Clin. Oncol. 9, 694-704.
19. Stites, D. P., Terr, A. I., and Parslow, T. G. (1994). In Basic and Clinical Pharmacology, 8th ed. Appleton & Lange Paramount Publishing Business and Professional Group, Norwalk, CT.
20. Smith, K. A. (1988). Interleukin-2: Inception, impact, and implications. Science 240, 1169-1176.
21. Vial, T., and Descotes, J. (1992). Clinical toxicity of interleukin-2. Drug Safety 7, 417-433.
22. Whittington, R., and Faulds, D. (1993). Interleukin-2: A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46, 446-514.
23. Winkelhake, J. L., and Gauny, S. S. (1990). Human recombinant Interleukin-2 as an experimental therapeutic. Pharmacol. Rev. 42, 1-28.
24. Wolfgang, G. H. I., Chen, S., Giedlin, M., Braeckman, R., and Johnson, D. (1997). Designing non-clinical safety evaluation programmes for interferons and interleukins: A personal view. In Safety Evaluation of Biotechnologically-Derived Pharmaceuticals: Facilitating a Scientific Approach. CMR Proc., Kluwer Academic, in press.
25. Zhang, J., Wenthold, R. J., Yu, Z., Herman, E. H., and Ferrans, V. J. (1995). Characterization of the pulmonary lesions induced in rats by human recombinant interleukin-2. Toxicol. Pathol. 23, 653-666.